fr 901379 profile

FR 901379: a water- soluble Echinocandin compound; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	44352613
CHEMBL ID	1161027
MeSH ID	M0286133

Synonym
fr901379
fr-901379
CHEMBL1161027
fr 901379
KAPLTEIQCKDUAT-WAULFNKYSA-N

Bioassays (24)

Assay ID	Title	Year	Journal	Article
AID47230	Compound was tested for inhibitory activity against 1,3-beta-glucan synthase from Candida albicans 6406	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID47095	In vivo effective dose for antifungal activity on sc administration in female mice infected with 2.5*10e6 cells/mL of Candida albicans at day 10	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162079	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of lungs positive/number tested for 8 weeks; 2/5	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID50138	In vitro antifungal activity against Candida krusei YC109 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID47237	In vitro antifungal activity against Candida albicans FP578 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID89934	Lytic concentration for hemolytic activity in human by akaishi method	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID37576	In vitro antifungal activity against Aspergillus niger ATCC 9642 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID47239	In vitro antifungal activity against Candida albicans FP629 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162077	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of lungs positive for trophozoites/number tested for 8 weeks; 0/5	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162072	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of cysts/lungs for 3 weeks	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID48826	In vitro antifungal activity against Candida utilis YC123 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID47240	In vitro antifungal activity against Candida albicans FP633 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID47096	In vivo effective dose for antifungal activity on sc administration in female mice infected with 2.5*10e6 cells/mL of Candida albicans at day 14	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID133425	Minimum lytic concentration that lysed red blood cells in mouse	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID48608	In vitro antifungal activity against Candida tropicalis YC118 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162075	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of lungs positive for lesions/number tested for 8 weeks; 0/5	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162074	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of lungs positive for lesions/number tested for 3 weeks; 0/5	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID47238	In vitro antifungal activity against Candida albicans FP582 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162076	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of lungs positive for trophozoites/number tested for 3 weeks; 0/5	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID89947	Minimum lytic concentration that lysed red blood cells in human	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID55192	In vitro antifungal activity against Cryptococcus neoformans YC203 at 30 degrees C for 48 hr	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID37561	In vitro antifungal activity against Aspergillus fumigatus FD050 at 37 degrees C for 22h	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162073	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of cysts/lungs for 8 weeks	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
AID162078	Evaluated for inhibitory growth of Pneumocystis carinii cysts in lungs administered at the dose of 10 mg/kg expressed as number of lungs positive/number tested for 3 weeks; 0/5	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (8.33)	18.2507
2000's	6 (50.00)	29.6817
2010's	4 (33.33)	24.3611
2020's	1 (8.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	2	1
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	3.15	1	macrolide lactam	bacterial metabolite; immunosuppressive agent
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	4.78	5	antibiotic antifungal drug; echinocandin	antiinfective agent
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
cilofungin cilofungin: a cyclic hexapeptide echinocandin; a modified form of Echinocandin B; antimycotic agent against Candida albicans. cilofungin : A cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus spp. By inhibiting the conversion of lanosterol to ergosterol, it invades a fungus' ability to synthesize cell walls. A modified form of echinocandin B, it is an antimycotic agent against Candida albicans.	2	1	antibiotic antifungal drug; echinocandin	antiinfective agent
hygromycin b [no description available]	2.05	1
echinocandin b echinocandin B: a cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity; inhibits beta-1,3-glucan synthesis. echinocandin B : A cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity.	2.05	1

Condition	Relationship Strength	Studies
Candida Infection [description not available]	3.34	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.4	2
Extravascular Hemolysis [description not available]	2	1
P carinii Pneumonia [description not available]	2.4	2
Bronchial Cyst [description not available]	2	1
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	3.34	2
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2	1
Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	2.4	2
Aspergillus Infection [description not available]	2.95	1
Fungal Diseases [description not available]	2.95	1
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	2.95	1
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	2.95	1
Mycoses Diseases caused by FUNGI.	2.95	1

fr 901379

Description

Cross-References

Synonyms (5)

Bioassays (24)

Research

Studies (12)

Market Indicators

Research Demand Index: 12.72

Study Types

fr 901379

Description

Cross-References

Synonyms (5)

Bioassays (24)

Research

Studies (12)

Market Indicators

Research Demand Index: 12.72

Study Types

Related Drugs (8)

Related Conditions (13)